Article
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
JAMA - 23 Nov 2011
Mega Jessica L, Hochholzer Willibald, Frelinger Andrew L, Kluk Michael J, Angiolillo Dominick J, Kereiakes Dean J, Isserman Steven, Rogers William J, Ruff Christian T, Contant Charles, Pencina Michael J, Scirica Benjamin M, Longtine Janina A, Michelson Alan D, Sabatine Marc S
Abstract excerpt
CONTEXT: Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-fun...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
